Zobrazeno 1 - 10
of 102
pro vyhledávání: '"Gerald H. Clamon"'
Autor:
Muhammad Furqan, Travis P. Snyders, Mohammed U. Saqlain, Sarah L. Mott, Douglas Laux, Anthony Snow, Carryn M. Anderson, John M. Watkins, Gerald H. Clamon
Publikováno v:
Cancer Medicine, Vol 8, Iss 6, Pp 2730-2739 (2019)
Abstract Background High‐dose cisplatin (Cis) is a preferred systemic agent for concurrent chemoradiation (CRT) in locally advanced head and neck squamous cell cancer (LAHNSCC) patients. As some patients are unable to tolerate Cis, this study compa
Externí odkaz:
https://doaj.org/article/25a0e21ebfab4140b5bcf8f1597d60a9
Autor:
Kristin Plichta, MD, PhD, Nathan Camden, BS, Muhammed Furqan, MD, Taher Abu Hejleh, MBBS, Gerald H. Clamon, MD, Jun Zhang, MD, PhD, Ryan T. Flynn, PhD, Sudershan K. Bhatia, MD, PhD, Mark C. Smith, MD, John M. Buatti, MD, Bryan G. Allen, MD, PhD
Publikováno v:
Advances in Radiation Oncology, Vol 2, Iss 4, Pp 581-587 (2017)
Purpose: The adrenal glands are a common site of metastases because of their rich blood supply. Previously, adrenal metastases were treated with systemic chemotherapy or, more rarely, with surgical resection or palliative radiation therapy. Stereotac
Externí odkaz:
https://doaj.org/article/8f05818fdec649d4b47c3f26df6e093b
Autor:
Paula M. Fracasso, Sherry A. Goodner, Jonathan D. Wildi, Michael J. Naughton, Gerald P. Linette, Ramaswamy Govindan, Benjamin R. Tan, Kristie A. Blum, Gary J. Jones, Tillman E. Pearce, Daniel J. Levitt, Gerald H. Clamon
Publikováno v:
Am J Clin Oncol
BACKGROUND: Human leukocyte antigen (HLA)-DR, a member of the major histocompatibility complex (MHC) class II antigen family, is a target for antibody-based therapeutics. Apolizumab (Hu1D10, Remitogen(™)), a humanized IgG1 monoclonal anti-HLA-DR ß
Autor:
Gerald H. Clamon, Carryn M. Anderson, Anthony N. Snow, Sarah L. Mott, Mohammed U Saqlain, Muhammad Furqan, Douglas Earl Laux, J.M. Watkins, Travis Snyders
Publikováno v:
Cancer Medicine, Vol 8, Iss 6, Pp 2730-2739 (2019)
Cancer Medicine
Cancer Medicine
Background High-dose cisplatin (Cis) is a preferred systemic agent for concurrent chemoradiation (CRT) in locally advanced head and neck squamous cell cancer (LAHNSCC) patients. As some patients are unable to tolerate Cis, this study compares the tox
Autor:
Gerald H. Clamon, Sneha Phadke
Publikováno v:
Critical Reviews in Oncology/Hematology. 138:173-177
Pre-clinical data has shown that beta adrenergic stimulation can affect the development and progression of many types of cancer. The use of beta blockers as an anti-neoplastic therapy has been studied in retrospective trials and observational trials,
Autor:
Gerald H. Clamon, Sarah L. Mott, John Keech, Kalpaj R. Parekh, Gideon K D Zamba, Mark D. Iannettoni, Bryan G. Allen, Laith Abushahin, Muhammad Furqan, Taher Abu Hejleh
Publikováno v:
Anticancer Research. 38:5247-5251
BACKGROUND: The tolerability of adjuvant chemotherapy in esophageal cancer is unclear. PATIENTS AND METHODS: This was a phase II trial of adjuvant paclitaxel in patients with esophageal cancer after trimodality treatment. Patients with residual viabl
Publikováno v:
J Oncol Pharm Pract
BackgroundTargeted oral agents are now increasingly being utilized in cancer treatment, but are expensive. Changing the dose of these medications due to toxicity or discontinuation secondary to disease progression or death causes waste from unused me
Autor:
Nathan Camden, Sudershan K. Bhatia, Jun Zhang, Muhammed Furqan, Bryan G. Allen, Kristin A. Plichta, Gerald H. Clamon, Taher Abu Hejleh, Ryan T. Flynn, Mark C. Smith, John M. Buatti
Publikováno v:
Advances in Radiation Oncology, Vol 2, Iss 4, Pp 581-587 (2017)
Advances in Radiation Oncology
Advances in Radiation Oncology
Purpose The adrenal glands are a common site of metastases because of their rich blood supply. Previously, adrenal metastases were treated with systemic chemotherapy or, more rarely, with surgical resection or palliative radiation therapy. Stereotact
Autor:
Gerald H. Clamon, Mark A. Socinski, Neal Ready, Ying Zhang, Everett E. Vokes, Walter J. Curran, Benjamin Movsas, Xiaofei Wang, Steven E. Schild, Jeffrey D. Bradley, Joan H. Schiller, George R. Blumenschein, Thomas E. Stinchcombe, Herbert Pang, Harvey J. Cohen, Ramaswamy Govindan, Wallace Akerley, Karen Kelly
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 35, iss 25
Stinchcombe, TE; Zhang, Y; Vokes, EE; Schiller, JH; Bradley, JD; Kelly, K; et al.(2017). Pooled analysis of individual patient data on concurrent chemoradiotherapy for stage III non-small-cell lung cancer in elderly patients compared with younger patients who participated in US national cancer institute cooperative group studies. Journal of Clinical Oncology, 35(25), 2885-2892. doi: 10.1200/JCO.2016.71.4758. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/0j4582gf
Stinchcombe, TE; Zhang, Y; Vokes, EE; Schiller, JH; Bradley, JD; Kelly, K; et al.(2017). Pooled analysis of individual patient data on concurrent chemoradiotherapy for stage III non-small-cell lung cancer in elderly patients compared with younger patients who participated in US national cancer institute cooperative group studies. Journal of Clinical Oncology, 35(25), 2885-2892. doi: 10.1200/JCO.2016.71.4758. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/0j4582gf
Purpose Concurrent chemoradiotherapy is standard treatment for patients with stage III non–small-cell lung cancer. Elderly patients may experience increased rates of adverse events (AEs) or less benefit from concurrent chemoradiotherapy. Patients a
Publikováno v:
The Journal of Community and Supportive Oncology. 15:e135-e141